Extendicare Announces Proposed Changes to Board of Directors




Extendicare Announces Proposed Changes to Board of Directors

MARKHAM, Ontario, March 18, 2026 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced that its board of directors (“Board of Directors” or “Board”) has nominated Josh Blair and Leslee Thompson for election as new Board members at the Company’s upcoming annual meeting of shareholders to be held on April 16, 2026 (the “Meeting”).

Extendicare also announced that current Board members Alan Torrie, Chair of the Board, and Donna Kingelin will not stand for re-election at the Meeting following over 10 years of service.

Alan’s leadership and vision during his nine years as Chair enabled the transition of Extendicare from its real estate focus to a new business model focused on health services. Donna chaired the HR Committee and subsequently the Quality and Risk Committee during her tenure, building pivotal capabilities that are core to the Company’s health services mandate. Extendicare and the Board express their deepest appreciation and gratitude to Alan and Donna for their outstanding service, invaluable contributions, and dedication during their tenures as directors of Extendicare.

The remaining seven current members of the Board, each of whom is an incumbent director, will stand for re-election at the Meeting, as further described in the Company’s management information and proxy circular dated March 5, 2026.

Assuming his re-election at the Meeting, it is expected that current director Samir Manji will be appointed as Chair of the Board immediately following the Meeting. Mr. Manji is the Executive Chair of RFA Financial Inc. and founder and CEO of Sandpiper Group, a Vancouver-based real estate private equity firm. Mr. Manji has been involved in over $10 billion in hospitality, seniors’ housing and multifamily residential real estate transactions and has over 30 years of experience in real estate and seniors’ housing, including as founder, Chairman and CEO of Amica Mature Lifestyles Inc. Mr. Manji has been a member of the Board and major shareholder of Extendicare since 2019.

Mr. Blair is the Co-Founder and Chief Executive Officer of Impro.AI, a high-tech company that enables corporations and their employees to accelerate their growth through AI-powered workforce insights and performance mentoring. He brings more than 30 years of experience in executive and board roles within the public and private capital markets across multiple industries, including AI and data services, health care and telecommunications. From 1995 through 2019, Mr. Blair served in senior leadership roles at TELUS Corporation, including as Group President overseeing TELUS Digital, TELUS Health, TELUS Business, TELUS Agriculture and TELUS Ventures.

Ms. Thompson is a corporate director, independent consultant and health care expert. She most recently served as President and CEO of Health Standards Organization and Accreditation Canada (2016–2026), two global not-for-profit organizations that certify and promote quality across Canada and in health organizations in 45 countries. Starting out as an ICU nurse, Ms. Thompson has led multiple organizations in both public and private sectors and has served on public and private boards. She was CEO of Kingston General Hospital (2009–2016), and served as a senior executive at Medtronic Canada, Cancer Care Ontario, Sunnybrook Health Sciences Centre, University Health Network and the Capital Health Authority in Edmonton.

“It has been very gratifying to play a part in transitioning Extendicare to a new business model that has enabled its emergence as a leading health services company in Canada,” said Alan Torrie, outgoing Chair of the Board. “I am confident that Samir and the rest of the Board will continue our track record of good governance practices to shepherd Extendicare’s strategy to expand access to care in the community.”

About Extendicare 
Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Network brands. We are committed to delivering quality care to meet the needs of the growing seniors’ population, inspired by our mission to provide people with the care they need, wherever they call home. We operate a network of 99 long-term care homes (59 owned, 40 under management contracts), deliver approximately 14.0 million hours of home health care services annually, and provide group purchasing services to third parties representing approximately 153,600 beds across Canada. Extendicare proudly employs approximately 23,000 individuals and manages an additional 5,000 individuals through its joint ventures, all of whom are highly qualified, trained and dedicated team members who are passionate about providing high-quality care and services to help people live better.

Extendicare contact:
David Bacon, Executive Vice President and Chief Financial Officer
T: (905) 470-4000
E: david.bacon@extendicare.com
www.extendicare.com

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)




Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026), taking place March 16–20, 2026, in Atlanta, Georgia.

Mr. Mehta will participate in two sessions focused on the evolving intersection of data engineering and artificial intelligence:

• From Risk to Reward: Modernizing the Data Estate to Power Enterprise AI
  Wednesday, March 18, 4:30PM – 5:05PM alongside Dipti Borkar, VP & GM OneLake & ISVs at Microsoft and Tripti Sethi, Data & AI Lead at Avanade.
• Agentic Data Engineering on Microsoft Fabric: Building Adaptive Pipelines
  Thursday, March 19, 4:15PM – 5:15PM alongside Nina Arora-Rowland, Data and AI Practice Lead at Avanade/Accenture, and Colin Pop, Senior Director, Analytics Architect at Avanade.

The sessions will explore how agentic AI is transforming modern data engineering, shifting pipelines from static, rules-based systems to adaptive, context-aware workflows. Topics will include emerging architectural patterns, real-world applications, and key considerations around governance, trust, and enterprise readiness as organizations adopt more autonomous data environments.

These themes align with Tevogen.AI’s broader efforts to apply advanced machine learning to biomedical discovery, including its published international patent application (WO 2025/129197), which outlines novel systems for predicting immunologically active peptides.

FabCon is Microsoft’s premier conference dedicated to its Fabric data platform, bringing together industry leaders, engineers, and innovators to explore the future of data and AI.

For more information or to connect with Mittul Mehta during the conference, please contact mittul.mehta@tevogen.com.

About Tevogen

Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.

Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.

Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.

Contact

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8feb8757-d993-45e3-a5da-3c4087c40abb

Azalea Therapeutics Highlights Nature Publication Demonstrating In Vivo Site-Specific TRAC-CAR T Cell Engineering




Azalea Therapeutics Highlights Nature Publication Demonstrating In Vivo Site-Specific TRAC-CAR T Cell Engineering

• Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea’s proprietary in vivo CAR T platform
• Peer-reviewed publication demonstrates stable, cell-specific transgene expression through in vivo site-specific integration of large DNA payloads
• Findings show integration of a promoterless CAR at the TRAC locus enables physiologic CAR expression and durable anti-tumor activity in preclinical models

BERKELEY, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today highlighted the publication of foundational research in Nature describing in vivo site-specific genomic integration to reprogram T cells. The research originated as an academic collaboration between the Eyquem laboratory at the University of California, San Francisco and the Doudna laboratory at the University of California, Berkeley. Three of the study’s authors – Justin Eyquem, Ph.D., Jenny Hamilton, Ph.D. and Jennifer Doudna, Ph.D. – subsequently co-founded Azalea Therapeutics to advance precise, programmable in vivo cell engineering toward the development of next-generation in vivo CAR T and other cell-based therapies.

The publication, titled “In vivo site-specific engineering to reprogram T cells,” demonstrates that stable and cell-specific transgene expression can be achieved through in vivo integration of large DNA payloads using a two-vector system consisting of enveloped delivery vehicles (EDVs) and adeno-associated viruses (AAVs). In preclinical models, the approach enabled targeted integration of a promoterless chimeric antigen receptor (CAR) transgene at the TRAC locus, resulting in physiologic CAR expression, robust T cell expansion and durable anti-tumor activity.

The research shows that placing CAR expression under control of the endogenous T cell receptor alpha (TRAC) promoter produces regulated CAR expression compared to conventional approaches relying on random integration or constitutive exogenous promoters. In humanized mouse models of B cell aplasia and hematologic malignancies, in vivo-generated TRAC-CAR T cells achieved therapeutic levels of CAR-positive T cells and sustained tumor control.

“This work demonstrates that stable, cell-specific transgene expression can be achieved through in vivo site-specific integration,” said Justin Eyquem, Ph.D., co-founder of Azalea Therapeutics and associate professor of medicine at UCSF. “By integrating a promoterless CAR into the TRAC locus, we place expression under control of the endogenous T cell promoter, resulting in physiologic regulation and durable functional activity in preclinical models. These findings establish a foundation for precise in vivo T cell engineering without ex vivo manufacturing.”

The research further describes optimization of both delivery components, including evolution of an AAV variant for improved T cell targeting and incorporation of an anti-CD3-targeted EDV to enhance specificity and activation. In humanized mouse models, the optimized system enabled generation of TRAC-CAR T cells representing up to ~20% of splenic T cells following a single administration, accompanied by complete B cell aplasia and tumor clearance.

“The research described in this publication establishes the scientific foundation for precise, programmable CAR insertion directly inside the body,” said Jenny Hamilton, Ph.D., co-founder, president and chief executive officer of Azalea Therapeutics. “At Azalea, we are building on these findings with our proprietary EDV-based platform to advance in vivo CAR T programs toward clinical development. Our goal is to generate physiologically regulated, durable CAR T cells in patients through targeted genomic integration, while avoiding the complexity of ex vivo cell manufacturing.”

Azalea is advancing TRAC-targeted in vivo CAR T programs toward IND-enabling studies, building on the foundational work described in this publication, which is available online in Nature.

About Azalea Therapeutics
Azalea Therapeutics is a biotechnology company redefining precision genomic medicines in vivo. Its proprietary Enveloped Delivery Vehicles (EDV) platform is engineered to deliver transient CRISPR-Cas9 cargo to specific cells in the body for site-specific genome editing with curative intent. Azalea’s first programs leverage T cell-targeting EDVs and highly efficient T cell-tropic AAVs to enable programmable CAR gene insertion at a defined genomic locus, placing expression under control of the cell’s endogenous promoter for physiologic and sustained activity. This approach aims to generate potent, durable and safe therapies directly inside patients, avoiding the complexity of ex vivo manufacturing and unlocking new treatment modalities – including in vivo CAR T cell therapies – across cancer, autoimmune disease and genetic disorders. Azalea is headquartered in Berkeley, California. For more information, please visit azaleatx.com and follow us on LinkedIn.

CONTACT: Contact:
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory
noopur@azaleatx.com

Totus Medicines Presents Phase 1a Clinical Data for TOS-358, a Covalent PI3Ka Inhibitor, at ESMO TAT 2026




Totus Medicines Presents Phase 1a Clinical Data for TOS-358, a Covalent PI3Ka Inhibitor, at ESMO TAT 2026

Oral presentation of Ph 1a clinical data highlights potential best-in-class drug profile in heavily pretreated patients with PI3Ka-mutant metastatic breast cancer and other solid tumors

Overall, TOS-358 demonstrated 50% clinical benefit rate (CBR), 75% disease control rate (DCR) and 45% of patients remained on drug for >24 weeks

67% of PI3K/AKT/mTOR (“PAM”)-resistant patients and 100% of PAM-intolerant patients achieved clinically meaningful disease control

TOS-358 demonstrated a class-leading safety profile with no evidence of bone marrow, hepatic, ocular, or dermatologic toxicities (rash or stomatitis/mucositis), and <5% G2 diarrhea or nausea. Hyperglycemia requiring insulin for ongoing blood glucose control was <4% – positioning TOS-358 well for combination therapies

Ph1b initiated in January 2026, exploring doublet- and triplet combination with fulvestrant & CDK4/6 inhibitors

EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Totus Medicines, a clinical stage, precision medicine company leveraging a novel covalent DNA-encoded library + AI-powered small molecule drug discovery platform to advance a differentiated pipeline of therapeutics against high-value, historically difficult to drug targets in multiple therapeutic areas, today announced the presentation by Dr. Antonio Giordano of Dana Farber Cancer Center of new clinical data for TOS-358, its lead oral covalent PI3Ka inhibitor, in an oral presentation at the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Congress in Paris, France.

“TOS-358 was designed to overcome the limitations of currently available PI3Ka inhibitors by delivering sustained and specific, >90% covalent inhibition of the target combined with a best-in-class safety profile,” said Zelanna Goldberg, M.D., Chief Medical Officer of Totus Medicines. “We are very encouraged by the early clinical efficacy data, which demonstrate durable tumor control and class-leading tolerability in heavily pretreated patients, including those who had previously progressed on other PI3K pathway therapies.

“TOS-358 is amongst the most interesting agents in this class to emerge. It appears to be a well-tolerated and straightforward drug to give for PI3Ka mutant disease with early data suggesting the potential for meaningfully durable tumor control. This may help inhibit tumor growth and maintain quality of life, which is a promising combination for our patients” said Dr. Antonio Giordano.

TOS-358 is an oral, highly selective, pan-mutant, covalent PI3Ka inhibitor that achieves >95% continuous target engagement for deep and durable inhibition of PI3K-AKT signaling which is required for optimal efficacy and durability.

Phase 1a Key Clinical Findings:

Clinical results from the efficacy cohort demonstrated encouraging anti-tumor activity and durability of response:

Overall efficacy profile:

• CBR: 50%
• DCR: 75%
• ORR: 15%
• ≥20% tumor shrinkage: 40%
• Patients on therapy for ≥24 weeks: 45%

Clinically meaningful disease control in heavily pre-treated patients:

• DCR in PAM-resistant patients: 67%
• DCR in PAM-intolerant patients: 100%

Class-leading Safety & Tolerability Profile:

TOS-358 demonstrated a favorable and differentiated safety profile, with minimal gastrointestinal or epithelial toxicities.

Key observations included:

• No bone marrow toxicity
• No hepatic toxicity
• No renal toxicity
• No ocular symptoms
• No rash
• No stomatitis or mucositis
• <5% of patients required medication for nausea or diarrhea

Hyperglycemia, an expected on-target effect of PI3Ka inhibition, was primarily low grade and manageable with oral medications. Only 3.6% (2/54 pts) required ongoing insulin, which is similar to, or lower than, other PI3Ka inhibitors in development including mutant selective and/or allosteric compounds.

Phase 1b study design:

TOS-358 is currently being evaluated in an ongoing Ph1b study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of TOS-358 in combination with fulvestrant and in combination with fulvestrant and CDK inhibitors in patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer. Initial data from these combination cohorts are expected to be presented at future medical and scientific conferences.

About Totus Medicines
Totus Medicines is a clinical-stage, precision medicines company, discovering novel covalent small molecules against previously undrugged or difficult to drug targets, based on its proprietary AI-powered OmniDEL platform (DNA-encoded covalent library technology). The company’s lead program, TOS-358, the first and only covalent PI3Ka inhibitor in clinical development, has shown efficacy, response and long-term disease control with class-leading tolerability in breast, endometrial and head & neck cancers. The company’s lead pre-clinical program is targeting IRF5, a key genetically validated but previously undrugged target across multiple I&I indications.

For more information, please visit www.totusmedicines.com.

Contact:
ir@totusmedicines.com 

External Contact:
Brian Mullen
LifeSci Advisors, LLC
Managing Director
bmullen@lifesciadvisors.com 
+1.203.461.1175 

Centre for Neuro Skills Expands Employer Partnerships Strategy, Appoints Jay Varma as Director




Centre for Neuro Skills Expands Employer Partnerships Strategy, Appoints Jay Varma as Director

CNS strengthens its engagement with employers, health plans and benefits advisors to expand access to specialized neuro center of excellence

BAKERSFIELD, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Centre for Neuro Skills (CNS), a national provider of brain injury rehabilitation and neuro-specialty care, has appointed Jay Varma as director of employer partnerships, a strategic leadership role designed to expand the organization’s collaboration with employers, health plans, benefits brokers and consultants.

Jay Varma,
Director of Employer Partnerships at
Centre for Neuro Skills

As employers increasingly look to specialized Centers of Excellence to address complex neurological conditions and improve workforce recovery outcomes, CNS is expanding its engagement with the employer and benefits ecosystem. Varma will help advance CNS’s role as a Neuro Center of Excellence within employer and health plan ecosystems.

With nearly a decade of enterprise experience across health technology, employer health benefits, biotech and life sciences, including roles at Amazon (One Medical), One Medical and BioXcel/Inveni AI, Varma brings deep expertise in employer health solutions, benefits strategy and C-suite partnership development. At One Medical and Amazon, she worked with large, self-insured employers across the West Coast to expand access to high-quality care through employer-sponsored benefits programs. Her background in specialty care, employer health strategy and enterprise partnerships positions her well to expand CNS’s reach into the employer market.

“Neurological conditions—from traumatic brain injury and stroke to concussion, cognitive complications and long COVID, carry serious and often hidden costs for employers, including extended disability, lost productivity, and fragmented care pathways,” said David Harrington, president and CEO of Centre for Neuro Skills. “Jay’s arrival signals our commitment to solving that problem directly with employers. CNS has 45 years of clinical expertise and outcomes data. Jay’s role is to help translate that expertise into meaningful partnerships with employers— ensuring access, measurable outcomes and better workforce recovery.”

While CNS has long served patients whose care was supported through employer-sponsored benefits, the creation of this role formalizes a direct-to-employer strategy. Varma will work with employers, brokers and consultants to structure partnerships that provide employees with coordinated access to CNS’s full care continuum. The specialty program is set to support in-person day treatments and telerehabilitation for various neuro-injuries/conditions as well as intensive in-patient rehab for catastrophic and traumatic brain injuries. This care is supported by clinical data and outcomes reporting that benefits decision-makers require.

“Employers today are under growing pressure to manage the long-tail impact of neurological conditions—from concussion and stroke to complex brain injuries—which often fall outside the scope of traditional benefits design,” said Varma. “CNS brings together decades of clinical expertise, outcomes data and a full continuum of neurorehabilitation care. My focus is helping employers and their advisors better understand how specialized neurological care can support workforce recovery, improve employee quality of life and reduce the long-term costs associated with fragmented care pathways.”

CNS’s employer partnership initiative reflects a broader shift in how companies are addressing complex medical conditions through specialized Centers of Excellence that improve outcomes while reducing long-term costs.

Varma joins CNS with a career that spans enterprise healthcare solutions, specialty pharma and biotech AI/ML platform strategic sales. She holds a M.S. degree in Pharmacology.

About Centre for Neuro Skills 

Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. Recognized as one of America’s Greatest Midsize Workplaces 2025 by Newsweek, CNS covers a full spectrum of advanced care, from residential and assisted living to outpatient and day treatment. Founded by Dr. Mark Ashley in 1980, CNS has eight locations in California and Texas. For more information, visit neuroskills.com, Facebook, X, LinkedIn and YouTube. For a video overview, visit CNS’s YouTube channel. 

Media note: To request an interview with CNS leadership or clinical staff, contact Robin Carr at 415.766.0927 or CNS@landispr.com. 

Media Contact: 
Landis Communications Inc. 
Robin Carr 
415.766.0927 
CNS@landispr.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5c455fa5-3851-44db-a709-2163c02ad8cf

Cortisol Detox App Supports Healthy Fat Loss With Meal Plans and Mindfulness




Cortisol Detox App Supports Healthy Fat Loss With Meal Plans and Mindfulness

Cortisol Detox Combines Anti-Cortisol Diet, Workouts, and Meditation to Support Weight Loss

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) — Cortisol Detox offers a personalized weight-loss program designed to help individuals manage stress, reduce cortisol-related weight gain, and support healthy fat-loss. The app combines anti-cortisol meal plans, simple workouts, guided meditations, motivating challenges, and progress tracking to help users be consistent.

Personalized Wellness That Fits Everyday Life

App starts with an onboarding quiz evaluating stress levels, lifestyle, dietary preferences, and fitness. Then, Cortisol Detox creates a personalized anti-cortisol plan, including:

• 1000+ Anti-Cortisol Diet Recipes – Personalized meal plans to balance cortisol and support weight loss without restrictive dieting.
• 100+ Workouts & Exercises – Simple workouts, yoga routines, and meditation guides for stress reduction and fat loss.
• Guided Meditations – Tailored mindfulness exercises to reduce stress, boost confidence, and increase energy.
• Motivating Challenges – Daily and weekly challenges to maintain consistency and engagement.
• Nutrition & Health Guides – Expert advice on food, movement, and lifestyle from nutritionists, trainers, and psychologists.

Guided Workouts and Mindfulness for Stress Relief

Cortisol Detox program emphasizes convenience with short workouts, yoga sessions, and meditation exercises that fit busy schedules. The program adjusts to different ability levels, helping beginners and experienced users progress comfortably while building consistent habits.

Clear Billing and Transparency

Cortisol Detox app stands out with straightforward, transparent billing practices. Subscription details, pricing, and renewal terms are clearly presented before purchase, so users know exactly what to expect. Canceling a subscription is simple, ensuring full control without hidden conditions. 

Reliable and Responsive Customer Support

Customer support is a key strength of the Cortisol Detox app. Users can expect fast, helpful, and friendly assistance with any questions about plans, billing, or app features. This responsive customer support system ensures users stay focused on their progress rather than dealing with app issues.

Cortisol Detox App Reviews From the Wellness Community

Users on Reddit describe Cortisol Detox as a stress-focused wellness app that just works. The biggest benefit is removing guesswork – opening the app daily to find personalized meal plans, workouts, and meditations without wondering what comes next. 

For those seeking a structured and lasting approach to a stress-free lifestyle, Cortisol Detox provides a clear path to real results. A personalized plan can be started today, turning nutrition and movement into an effective routine.

Photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/54b4d882-04e7-4f02-b2fc-30251a4d8930

CONTACT: Contact: help@cortisoldetox.com

LiveWorld Reports 2025 Financial Results




LiveWorld Reports 2025 Financial Results

LiveWorld continues to increase its AI investment

CAMPBELL, Calif. and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) — LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for the year 2025.

Twelve Months 2025 Financial and Business Highlights

• Total twelve-month revenues of $11.1 million
• Healthcare revenues of $10 million in 2025
• Net income from operations of $326,000
• Net Cash of $5.7 million

Management Commentary

“We saw our 2025 revenues drop slightly when we compare to our 2024 revenues as our clients delt with the volatility and uncertainty of the current economy,” remarked David Houston, Chief Financial Officer, of LiveWorld. “While our revenues were down approximately 2% year-over-year we did improve our net income for the same period by over 376%. As we move into 2026, we will continue our investment in AI which will have an impact on the profits of the company. Finally, our clients have begun to expand their budgets with us again. Based on current bookings and forecasts we are cautiously optimistic our total revenues for 2026 will exceed our totals for 2025.”

“We have expanded our investment in AI products, announced our AI strategy and are steadily launching new AI based solutions,” said Peter Friedman, LiveWorld Chairman and CEO. “ Initial client response is positive and we expect these products to be the basis for revenue growth in the years to come.”

Financial Review for the twelve Months Ended December 31, 2025

Total revenues for the twelve months ended December 31, 2025 were approximately $11.1 million, as compared to approximately $11.3 million for the twelve months ended December 31, 2024. This was a decrease of approximately $208,000 or 2% period-over-period.

The company reported a net income for the twelve months of approximately $326,000 or 3% of total revenues. This compares to net income of approximately $69,000 or 1% of total revenues reported for the twelve months of 2024. This was an increase of approximately 376% when comparing the two periods.

The company finished the year with approximately $7.3 million in cash and cash equivalents, compared to approximately $6.6 million at the end of 2024. The net cash available for operations was approximately $5.7 million at the end of December 31, 2025, compared to the $6.2 million at the end of 2024. The company defines net cash available for operations as cash, less media expenditure commitments.

Detailed financial information may be downloaded at www.liveworld.com/ir or at https://www.otcmarkets.com/stock/LVWD/overview.

About LiveWorld

LiveWorld is a Human-Led, AI-Powered digital marketing agency and software company.  We unlock the full potential of social and digital media to transform customer relationships through integrated compliance, engagement, and insight solutions. 

Purpose-built for highly regulated healthcare and pharma brands, LiveWorld combines proactive compliance, expert-led social media moderation, dynamic community engagement, and AI-powered insights to help brands listen smarter, engage more meaningfully, and act with confidence. Our approach blends human expertise with advanced AI to deliver genuine human connections, ensure accuracy, safety, and relevance, turning real-world conversations into trusted intelligence and measurable business impact. 

LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in Campbell, California, with an additional office in New York City. Learn more at www.liveworld.com and @LiveWorld. 

“Safe Harbor” Statement Under The Private Securities Litigation Reform Act
This press release may contain forward-looking information concerning LiveWorld plans, objectives, future expectations, forecasts and prospects. These statements may include those regarding LiveWorld’s current or future financial performance including but not limited to lists of clients, revenue and profit, use of cash, investments, relationships and the actual or potential impact of stock option expense, and the results of its product development efforts. Actual results may differ materially from those expressed in the forward- looking statements made as a result of, among other things, final accounting adjustments and results, LiveWorld’s ability to attract new clients and preserve or expand its relationship with existing clients, LiveWorld’s ability to retain and attract high quality employees, including its management staff, the ability to deliver new innovative products in a timely manner, changing accounting treatments, and other risks applicable to the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update these forward-looking statements to reflect subsequent events or circumstances.

LiveWorld Contacts
IR Contact:
David Houston
LiveWorld
dhouston@liveworld.com
(408) 615-8496

PR Contact:
Matthew Hammer
LiveWorld
mhammer@liveworld.com
(737) 212-9739

LiveWorld Reports 2025 Financial Results




LiveWorld Reports 2025 Financial Results

LiveWorld continues to increase its AI investment

CAMPBELL, Calif. and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) — LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for the year 2025.

Twelve Months 2025 Financial and Business Highlights

• Total twelve-month revenues of $11.1 million
• Healthcare revenues of $10 million in 2025
• Net income from operations of $326,000
• Net Cash of $5.7 million

Management Commentary

“We saw our 2025 revenues drop slightly when we compare to our 2024 revenues as our clients delt with the volatility and uncertainty of the current economy,” remarked David Houston, Chief Financial Officer, of LiveWorld. “While our revenues were down approximately 2% year-over-year we did improve our net income for the same period by over 376%. As we move into 2026, we will continue our investment in AI which will have an impact on the profits of the company. Finally, our clients have begun to expand their budgets with us again. Based on current bookings and forecasts we are cautiously optimistic our total revenues for 2026 will exceed our totals for 2025.”

“We have expanded our investment in AI products, announced our AI strategy and are steadily launching new AI based solutions,” said Peter Friedman, LiveWorld Chairman and CEO. “ Initial client response is positive and we expect these products to be the basis for revenue growth in the years to come.”

Financial Review for the twelve Months Ended December 31, 2025

Total revenues for the twelve months ended December 31, 2025 were approximately $11.1 million, as compared to approximately $11.3 million for the twelve months ended December 31, 2024. This was a decrease of approximately $208,000 or 2% period-over-period.

The company reported a net income for the twelve months of approximately $326,000 or 3% of total revenues. This compares to net income of approximately $69,000 or 1% of total revenues reported for the twelve months of 2024. This was an increase of approximately 376% when comparing the two periods.

The company finished the year with approximately $7.3 million in cash and cash equivalents, compared to approximately $6.6 million at the end of 2024. The net cash available for operations was approximately $5.7 million at the end of December 31, 2025, compared to the $6.2 million at the end of 2024. The company defines net cash available for operations as cash, less media expenditure commitments.

Detailed financial information may be downloaded at www.liveworld.com/ir or at https://www.otcmarkets.com/stock/LVWD/overview.

About LiveWorld

LiveWorld is a Human-Led, AI-Powered digital marketing agency and software company.  We unlock the full potential of social and digital media to transform customer relationships through integrated compliance, engagement, and insight solutions. 

Purpose-built for highly regulated healthcare and pharma brands, LiveWorld combines proactive compliance, expert-led social media moderation, dynamic community engagement, and AI-powered insights to help brands listen smarter, engage more meaningfully, and act with confidence. Our approach blends human expertise with advanced AI to deliver genuine human connections, ensure accuracy, safety, and relevance, turning real-world conversations into trusted intelligence and measurable business impact. 

LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in Campbell, California, with an additional office in New York City. Learn more at www.liveworld.com and @LiveWorld. 

“Safe Harbor” Statement Under The Private Securities Litigation Reform Act
This press release may contain forward-looking information concerning LiveWorld plans, objectives, future expectations, forecasts and prospects. These statements may include those regarding LiveWorld’s current or future financial performance including but not limited to lists of clients, revenue and profit, use of cash, investments, relationships and the actual or potential impact of stock option expense, and the results of its product development efforts. Actual results may differ materially from those expressed in the forward- looking statements made as a result of, among other things, final accounting adjustments and results, LiveWorld’s ability to attract new clients and preserve or expand its relationship with existing clients, LiveWorld’s ability to retain and attract high quality employees, including its management staff, the ability to deliver new innovative products in a timely manner, changing accounting treatments, and other risks applicable to the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update these forward-looking statements to reflect subsequent events or circumstances.

LiveWorld Contacts
IR Contact:
David Houston
LiveWorld
dhouston@liveworld.com
(408) 615-8496

PR Contact:
Matthew Hammer
LiveWorld
mhammer@liveworld.com
(737) 212-9739

Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors




Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fellowship at Stanford University Medical Center and earned his M.D. from the Icahn School of Medicine at Mount Sinai, with additional degrees in engineering from the University of Pennsylvania and in finance from The Wharton School.

“As we continue advancing innovative solutions in women’s health, Dr. Eichenbaum brings a unique combination of clinical and technical expertise, along with deep financial insight, that will be invaluable to Femasys,” said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. “His experience evaluating and advising biotechnology and medical device companies adds an important strategic perspective to our Board, and we are thrilled to welcome him at this important stage in the Company’s growth.”

Dr. Eichenbaum commented, “Femasys is advancing innovative, non-surgical solutions designed to improve the patient experience while reducing cost and complexity in women’s reproductive care. I look forward to working with the Board and management team to support the Company’s continued growth and innovation.”

The Company also expresses its appreciation to Joshua Silverman for his service on the Board of Directors. His capital markets perspective and strategic counsel supported Femasys during a period of important growth and development.

About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed^® Intratubal Insemination (ITI), a groundbreaking first-step infertility treatment; FemSperm^®, a CLIA waived sperm preparation and analysis product line; and FemVue^®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrate that FemaSeed achieved more than double the pregnancy rates of traditional IUI, with a comparable safety profile and high patient and practitioner satisfaction.¹

FemBloc^® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec^®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.² For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.

Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

References
¹Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

²Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

Forward-Looking Statements 
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts: 
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting




Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

Selected for oral presentation at Clinical Trials Mini Symposium

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026.

The abstract was selected for oral presentation as part of the Clinical Trials Mini Symposium.

Oral Presentation

Title: First-in-human phase I study of PLN-101095, a first-in-class dual α_vβ₈/α_vβ₁integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)

Presenter: Timothy A. Yap, M.D., Ph.D., University of Texas, M.D. Anderson Cancer Center
Session: CTMS01: Updates in Anticancer Immunotherapies
Date: Saturday, April 18, 2026
Presentation Time: 10:21 a.m. – 10:31 a.m. Pacific Time
Location: Ballroom 6A – Upper Level – San Diego Convention Center

Oncology Program

PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins designed to overcome checkpoint resistance by blocking TGF-β activation in the tumor microenvironment. Pliant is currently conducting a Phase 1a/1b open-label, dose-escalation and indication expansion trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095, as monotherapy and in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company’s lead program is PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. Pliant’s early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com